ImmunoCellular Therapeutics to Report First Quarter 2015 Financial Results on May 11, 2015; Conference Call and Webcast to be Held on May 12, 2015

Thursday, April 30, 2015

LOS ANGELES, April 30, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the first quarter 2015 on Monday, May 11, 2015. The Company also plans to hold a conference call and webcast on Tuesday, May 12, 2015, at 5:00 pm ET to discuss the first quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO.

ImmunoCellular Therapeutics Logo.

 

LIVE CALL: 

(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 30452546.





WEBCAST:       

Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.

Investor Relations

Jane Green

415.348.0010 direct

415.652.4819 mobile

jane@jmgcomm.com

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-report-first-quarter-2015-financial-results-on-may-11-2015-conference-call-and-webcast-to-be-held-on-may-12-2015-300074854.html

SOURCE ImmunoCellular Therapeutics, Ltd.

TOP